Acquisition Impact The acquisition of ENCORE Research Group by Flourishresearch in 2024 suggests strategic consolidation in Florida clinical research networks, creating potential cross-sell opportunities for sponsors and vendors looking to scale trials across eight Florida sites and related capabilities.

Expanded Footprint ENCORE operates across multiple specialty sites in Florida with a long track record since 1997, presenting a ready-made network for sponsors seeking geographically diverse Phase 1-4 participation and streamlined site activation.

CTMS Advantage In-house Clinasyst Next Gen CTMS and a robust patient database of over 100,000 individuals position ENCORE as a data- and process-efficient partner, enabling faster patient recruitment and trial management for potential sponsors.

Moderate Scale With 11-50 employees and reported revenue between $1M-$10M, ENCORE represents a mid-market partner that can offer flexible collaboration terms, competitive pricing, and personalized site-level engagement for niche studies.

Tech and Infrastructure A tech-forward stack including AWS, Google Cloud, WordPress, Shopify and modern hosting indicates readiness to integrate sponsor tech, streamline documentation, and provide scalable digital experiences for trial operations and patient engagement.